AlphaMadera
Corcept Therapeutics Incorporated (CORT)
$80.35
-4.83 (-5.62%)Delayed quote.
Price history
Daily close- Start
- $74.17
- Latest close
- $81.12
- Period change
- +9.37%
- Period low
- $32.15
- Period high
- $123.57
Key metrics
- Market cap
- $8.77B
- Volume
- 1.43M
- Average volume
- 1.21M
- 52-week range
- $28.66 – $126.38
- Beta
- 0.45
- Last dividend
- —
- EPS (TTM)
- $0.52
- P/E ratio
- 154.51
- Revenue (TTM)
- $830.81M
- Net income (TTM)
- $54.90M
- Total assets
- $888.70M
- Total debt
- $9.42M
- Cash and equivalents
- $111.04M
Key financials (trailing twelve months).
Company profile
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Exchange
- NASDAQ
- CEO
- Joseph K. Belanoff
- Employees
- 730
- Headquarters
- Redwood City, CA, US
- IPO date
- 2004-04-14
- Website
- https://www.corcept.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $761.41M | $675.04M | $482.38M |
| Gross profit | $748.43M | $664.16M | $475.89M |
| Operating income | $44.80M | $136.95M | $107.28M |
| EBITDA | $68.35M | $162.83M | $126.92M |
| Net income | $99.65M | $139.73M | $106.14M |
| Diluted EPS | $0.82 | $1.23 | $0.94 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $120.50M | $127.67M | $135.55M |
| Total assets | $836.65M | $840.55M | $621.52M |
| Total liabilities | $188.85M | $160.96M | $114.81M |
| Total debt | $6.11M | $6.94M | $151.0K |
| Shareholders’ equity | $647.80M | $679.59M | $506.70M |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $142.00M | $198.07M | $127.04M |
| Capital expenditure | -$211.0K | -$2.17M | -$139.0K |
| Free cash flow | $141.78M | $195.90M | $126.90M |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 | Q1 2025Mar 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $256.15M | $164.90M | $202.12M | $207.64M | $194.43M | $157.21M |
| Gross profit | $252.09M | $162.02M | $199.58M | $203.04M | $191.00M | $154.81M |
| Operating income | $41.30M | -$49.60M | $4.49M | $10.22M | $26.68M | $3.42M |
| EBITDA | $46.79M | -$44.12M | $10.39M | $15.72M | $32.16M | $10.08M |
| Net income | $42.14M | -$31.20M | $24.29M | $19.67M | $35.15M | $20.55M |
| Diluted EPS | $0.36 | -$0.30 | $0.20 | $0.16 | $0.29 | $0.17 |
| Metric | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 | Q1 2025Mar 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $111.04M | $108.74M | $120.50M | $125.14M | $102.75M | $89.82M |
| Total assets | $888.70M | $814.88M | $836.65M | $823.61M | $801.72M | $846.46M |
| Total liabilities | $182.93M | $176.89M | $188.85M | $191.71M | $165.93M | $163.17M |
| Total debt | $9.42M | $9.64M | $6.11M | $6.36M | $6.61M | $6.83M |
| Shareholders’ equity | $705.78M | $637.99M | $647.80M | $631.90M | $635.79M | $683.28M |
| Metric | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 | Q1 2025Mar 31, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $33.54M | -$16.77M | $38.45M | $54.48M | $43.94M | $5.13M |
| Capital expenditure | -$2.53M | -$201.0K | -$50.0K | $0 | -$57.0K | -$104.0K |
| Free cash flow | $31.02M | -$16.97M | $38.40M | $54.48M | $43.88M | $5.02M |